A second baby with acute lymphoblastic leukemia (ALL) who received the experimental UCART19 injection of French biotech company Cellectis (Euronext Paris: ALCLS) remains in remission six months after treatment, according to reports.
The 16-month-old girl was found to be recovering from the previously incurable disease at Great Ormond Street Hospital in London, providing further excitement about the potential of Cellectis’ allogeneic gene-edited chimeric antigen receptor T-cell (CAR-T) immunotherapy in fighting cancer.
News on the latest case comes as the first infant continues to be in remission almost a year after receiving the treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze